{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:56:39Z","timestamp":1773017799240,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic myeloid leukaemia (CML) is rare in paediatric population, approximately 2\u20133% of leukaemia cases in children and 9% in adolescents. The introduction of tyrosine kinase inhibitors (TKIs) has significantly improved outcomes, but long-term use may lead to adverse endocrine effects and impact quality of life (QoL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective cross-sectional study evaluated 82 paediatric and young adult CML patients who were started on TKI therapy at &amp;lt;18 years of age. 71 patients were on TKI for &amp;gt;2 years and 11 patients were initiated on TKI during the study. Anthropometric measurements, Tanner staging, and laboratory parameters assessing endocrine function, bone health, glucose and lipid metabolism were evaluated. QoL was assessed with validated instruments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median duration of TKI exposure was 7.5 years. Short stature was observed in 15% (11\/71) of patients. Among those who were prepubertal at TKI initiation, 26.5% (9\/34) were found to have short stature. Low Bone mineral density was found in 35\u00b72% (24\/68). Vitamin D deficiency was found in 84% and subclinical hypothyroidism in 9\u00b78% (7\/71). Two patients had poor sperm quality. One male patient had infertility. There was less impact on glucose, lipid profile, and adrenal function. In the QoL analysis, social functioning was affected among the functional scales, while financial difficulties, appetite loss, and fatigue were impacted in the symptom scales. Overall, QoL scores for physical, psychosocial, and school functioning remained well-preserved, but longer TKI treatment duration was associated to lower scores in these domains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This comprehensive evaluation highlights the need for close monitoring of BMD in patients who are on long-term TKI therapy. Evaluation of all other endocrine functions can be done as clinically indicated.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1598104","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:29:14Z","timestamp":1751952554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term endocrine outcomes and quality of life in paediatric and young chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy: a prospective study from India"],"prefix":"10.3389","volume":"15","author":[{"given":"Rajiv","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitrakshi","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swasthik","family":"Upadhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Khadgawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid\u00a0leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.02.015","article-title":"Real-world experience of imatinib in pediatric chronic phase chronic myeloid leukemia: a single-center experience from India","volume":"20","author":"Ganguly","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.4103\/ijmr.IJMR_331_19","article-title":"Paediatric chronic myeloid leukaemia: Is it really a different disease","volume":"149","author":"Pushpam","year":"2019","journal-title":"Indian J Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MPH.0000000000002660","article-title":"Effect of imatinib mesylate\u00a0on growth in pediatric chronic myeloid leukemia: A systematic review and\u00a0meta-analysis","volume":"45","author":"Gupta","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Greyanguly","year":"2006","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase","volume":"12","author":"Chang","year":"2017","journal-title":"Target Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2068003","article-title":"Effects of imatinib on glycemic and lipid profiles: a retrospective cohort study","volume":"63","author":"Markovits","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/15648265040251S104","article-title":"The who multicentre growth reference study: planning, study design, and methodology","volume":"25","author":"de Onis","year":"2004","journal-title":"Food Nutr Bull"},{"key":"B13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1651-2227.2006.tb02378.x","article-title":"WHO Child Growth Standards based on length\/height, weight and age","volume":"95","author":"Group","year":"2006","journal-title":"Acta Paediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40746-016-0061-9","article-title":"Puberty-defining normal and understanding abnormal","volume":"2","author":"De Silva","year":"2016","journal-title":"Curr Treat Options Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12369","article-title":"Osteoporosis: the evolution of a diagnosis","volume":"277","author":"Lorentzon","year":"2015","journal-title":"J Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u2011S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B19","volume-title":"Quality of Life of Cancer Patients","year":"2017"},{"key":"B20","unstructured":"Pediatric Quality of Life Inventory TM\n          \n          \n            \n              PedsQL\n              TM"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19251","article-title":"Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era\u2014Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort","volume":"204","author":"Roy Moulik","year":"2024","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03042-1","article-title":"Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China","volume":"113","author":"Cai","year":"2021","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2019.1610119","article-title":"Effect of imatinib on growth in children with chronic myeloid leukemia","volume":"36","author":"Boddu","year":"2019","journal-title":"Pediatr Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e20162398","DOI":"10.2196\/jmir.7004","article-title":"SECTION ON ENDOCRINOLOGY. Bone densitometry in children and adolescents","volume":"138","author":"Bachrach","year":"2016","journal-title":"Pediatrics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e19150","DOI":"10.1097\/MD.0000000000019150","article-title":"Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia","volume":"99","author":"Deng","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03832-y","article-title":"Health-related quality of life in children with chronic myeloid leukemia in the chronic phase","volume":"148","author":"Zheng","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26028","article-title":"Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:29:18Z","timestamp":1751952558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1598104"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1598104","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"article-number":"1598104"}}